By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB6426, a national Category 1 new drug self-developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of advanced malignant tumors. The clearance advances a first-wave GPC3-targeting antibody-drug conjugate (ADC) — a class with no approved product worldwide — into U.S. clinical development.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Approval Type | Investigational New Drug (IND) |
| Product | TQB6426 |
| Drug Class | GPC3-targeting antibody-drug conjugate (ADC) |
| Indication | Advanced malignant tumors |
| Date | 03 Sept 2026 |
| Developer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd., subsidiary of Sino Biopharmaceutical |
| Next Steps | Initiation of U.S. clinical development program |
Drug Profile & Mechanism of Action
- Molecule: TQB6426, a GPC3-targeting antibody-drug conjugate (ADC) and national Category 1 new drug independently developed by Chia Tai Tianqing
- Target: GPC3, a cell-membrane glycoprotein barely expressed in normal adult tissues but highly expressed in hepatocellular carcinoma (HCC), where it serves as a biomarker for clinical diagnosis
- Target Breadth: GPC3 expression is also up-regulated in lung squamous cell carcinoma, ovarian cancer, and other solid tumors, positioning it as a highly promising target for targeted therapy and immunotherapy
- Preclinical Profile: Demonstrated potent target-binding affinity and selective cytotoxicity against tumor cells
- Differentiation: Bystander killing activity and in vivo anti-tumor efficacy superior to similar candidates, indicating best-in-class (BIC) potential
- Competitive Landscape: No GPC3-targeting ADC has been approved for marketing worldwide, leaving a wide-open therapeutic space
Preclinical Evidence & Development Outlook
| Attribute | Preclinical Finding |
|---|---|
| Target-binding affinity | Potent |
| Selective cytotoxicity | Demonstrated against tumor cells |
| Bystander killing activity | Superior to similar candidates |
| In vivo anti-tumor efficacy | Superior to similar candidates |
| Positioning | Best-in-class (BIC) potential |
Preclinical data position TQB6426 ahead of peer candidates in the nascent GPC3-ADC field, with an efficacy and bystander-killing profile that supports development across GPC3-expressing solid tumors. The FDA IND clearance opens the door to first-in-human evaluation in the United States alongside the molecule’s development trajectory in China.
Market Impact & Outlook
- White-space opportunity: With no GPC3-targeting ADC approved anywhere in the world, TQB6426 competes for a genuinely uncontested category rather than a crowded one
- Large addressable market: Hepatocellular carcinoma remains one of the most prevalent and lethal cancers in China and globally, with limited effective options in advanced stages
- Platform validation: The FDA acceptance validates Chia Tai Tianqing’s in-house ADC discovery capabilities and strengthens Sino Biopharmaceutical’s (HKG: 1177) innovation credentials
- Global expansion: U.S. IND clearance marks a concrete step in the group’s internationalization strategy, creating optionality for global trials and partnerships
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug development, clinical potential and market opportunity are forward-looking and subject to risks and uncertainties, including clinical trial outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech